CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin
HOUSTON, May 19, 2021 /PRNewswire/ — CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced open…
Comments Off on CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin